-
-
-
-
-
-
-
Belite Bio receives orphan drug status in Switzerland for retinal therapy
-
-
-
-
-
-
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $217 at Benchmark Following Business Update
-
-
-
-
-
-
-
Morgan Stanley Starts Belite Bio, Inc, ADR (BLTE) at Overweight
-
-
-
-
-
-
-
Belite Bio receives UK regulatory nod for Stargardt disease drug application
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
-
-
-
-
-
-
Belite Bio, Inc, ADR (BLTE) PT Raised to $60 at H.C. Wainwright
-
416,808 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

